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Abstract: Borrelia burgdorferi is highly susceptible to antibiotic treatment and the majority of patients profit from this treatment.
Antibiotic selection, dose and route of administration, and duration of therapy for Lyme disease depend on the patient’s clinical
manifestations and stage of disease, age, pregnancy status, as well as the presence of other concomitant diseases and/or allergies.
Despite an appropriate antibiotic therapy, about 10-20% of patients may show persistent or recurrent symptoms ("post-treatment
Lyme disease syndrome").
In  the  present  paper  we will  briefly  discuss  the  post-exposure  prophylaxis,  before  going on to  talk  over  the  current  therapeutic
approach regarding the management  of  Lyme disease according to  the  stage of  disease/clinical  manifestations.  Finally,  we will
discuss the main treatment-related phenomenon, the Jarisch-Herxheimer reaction, and the treatment modalities for special categories
of patients, namely pregnant women, subjects suffering from post-treatment Lyme disease syndrome, possible Borrelia-associated
skin manifestations, coinfections and Baggio-Yoshinary syndrome.
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1. INTRODUCTION
Lyme  disease  (LD)  is  a  tick-transmitted  multisystem  inflammatory  disease  caused  by  the  spirochete  Borrelia
burgdorferi  sensu  lato  [1  -  4].  In  particular  three  genospecies  have  been  considered  important  human  pathogens,
Borrelia burgdorferi sensu stricto in the USA and Europe, and Borrelia afzelii and Borrelia garinii in Europe and Asia
[5, 6]. Potential pathogenic Borrelia species include Borrelia bavariensis, Borrelia bissettii, B. kurtenbachii, Borrelia
Spielmanii, Borrelia lusitaniae, and Borrelia valaisiana [7]. The pathogenic Borrelia miyamotoi was identified in Japan
[8],  and  is  now known to  be  present  in  the  USA and Russia  [9],  and  recently  discovered  in  the  UK [10].  Borrelia
burgdorferi  is  highly  susceptible  to  antibiotic  treatment  and  the  majority  of  patients  profit  from  this  treatment.
Antibiotic selection, dose and route of administration, and duration of therapy for LD depend on the patient’s clinical
manifestations and stage of disease, age, pregnancy status, as well as the presence of other concomitant diseases and/or
allergies  [11,  12].  Importantly,  about  10-20%  of  patients  (especially  those  who  are  diagnosed  later),  following
appropriate antibiotic treatment, may have persistent or recurrent symptoms and are considered to have "post-treatment
Lyme disease syndrome" [13]. In some cases, other microorganisms may be cotransmitted through the tick bite [8, 12,
14]. Patients found to have coinfections should be treated with appropriate therapies.
In the present paper we will briefly discuss the post-exposure prophylaxis, before going on to talk over the current
therapeutic approach regarding the management of LD according to the stage of disease/clinical manifestations. Finally,
we  will  discuss  on  the  main  treatment-related  phenomenon,  the  Jarisch-Herxheimer  reaction,  and  the  treatment
modalities for special categories of patients, namely pregnant women, subjects suffering from post-treatment Lyme
disease syndrome, possible Borrelia-associated skin manifestations, coinfections and Baggio-Yoshinary syndrome.
* Address correspondence to this author at the Clinica Dermatologica, Università degli Studi di Trieste, IV piano Palazzina Infettivi-34100 Trieste,
Italy; Tel: +390403992056; Email: trevisan@units.it
Therapy of Lyme Disease The Open Dermatology Journal, 2016, Volume 10   71
2. POST-EXPOSURE PROPHYLAXIS
Chemoprophylaxis of LD after a tick bite has been the subject of debate in recent years. In the unique randomized,
double blind, placebo-controlled trial conducted, effective chemoprophylaxis was achieved using a single dose of 200
mg oral doxycycline within 72 hours of removal of Ixodes scapularis ticks [15]. The last guidelines from the Infectious
Diseases Society of America, recommend offering doxycycline prophylaxis to patients in the United States with known
Ixodes  scapularis  attachment  of  at  least  36  hours  within  72  hours  of  tick  removal.  This  recommendation  is  only
applicable in areas endemic to Borrelia burgdorferi  sensu lato,  where tick infection rates are at  least  20% [11, 14].
Prophylactic  antibiotic  therapy  may not  be  suitable  for  patients  with  bites  from ticks  other  than  Ixodes  scapularis;
furthermore, it is not currently recommended for those attacked by Ixodes ricinus in Europe [14].
Post-exposure  prophylaxis  is  not  without  risks;  indeed,  insufficient  prophylaxis  may  increase  the  potential  for
insidious progression of disease in the absence of seroconversion, and some authors speculate that inadequate antibiotic
therapy in the setting of prophylaxis may promote the development of antibiotic-resistant organisms. However, there are
currently no data showing acquired antibiotic resistance to be the cause of treatment-refractory LD or post-treatment
Lyme disease syndrome [14].
3.  EARLY  LOCALIZED  DISEASE  (ERYTHEMA  MIGRANS  ±  NONSPECIFIC  CONSTITUTIONAL
SYMPTOMS)
The  management  options  for  such  stage  of  disease  are  represented  by  oral  antimicrobial  therapies,  including
doxycycline  (200  mg/day,  divided  into  two  doses  daily;  pediatric  dose:  4  mg/kg/day),  amoxicillin  (1500  mg/day,
divided into three doses daily; pediatric dose: 50 mg/kg/day), or cefuroxime axetil (1 g/day, divided into two doses
daily; pediatric dose: 30 mg/kg/day) [12]. While ten days of therapy (range 10-21 days) are generally sufficient for
doxycycline,  a longer administration (at  least  14 days;  range 14-21 days) is  required for amoxicillin or cefuroxime
axetil, given the much shorter half-life of such β-lactam drugs. Therefore, for uniformity, a 14-day course of therapy is
advised for all of the first-line oral agents [11]. Doxycycline is generally preferred since it has the advantage of being
also  effective  for  treatment  of  human  granulocytic  anaplasmosis  and  Borrelia  lonestari  and  Borrelia  miyamotoi
infections (but not for babesiosis), which may occur simultaneously with early LD; however, it is contraindicated in
children <8 years of age and during pregnancy or lactation [11, 14, 16]. Cefuroxime axetil is usually considered as a
second-line treatment because of its  cost  [14].  Two small  studies found that  doxycycline (100 mg twice-daily) and
amoxicillin (500 mg three times a day, plus probenecid at the same dose), both administered for ten days in one study
and for three weeks in another, had a comparable efficacy in the treatment of early localized LD [17, 18]. Two other
studies on the treatment of erythema migrans compared cefuroxime axetil (500 mg twice per day for 20 days) with
doxycycline (100 mg 3 times per day for 20 days), demonstrating similar efficacy [19, 20]. In a separate randomized
trial of 43 children with erythema migrans, 2 different dosage regimens of cefuroxime axetil (20 mg/kg per day or 30
mg/kg  per  day)  were  found  to  have  efficacy  comparable  to  amoxicillin  (50  mg/kg  per  day)  [21].  Patients  who are
intolerant/allergic  to  amoxicillin,  doxycycline,  and  cefuroxime  axetil  may  be  alternatively  treated  with  macrolide
antibiotics (azithromycin at the dose of 500 mg orally per day (pediatric dose: 10 mg/kg per day with a maximum of
500 mg per day) for 7-10 days, clarithromycin at the dose of 500 mg orally twice per day (pediatric dose: 7.5 mg/kg
twice per day with a maximum of 500 mg per dose) for 14-21 days, or erythromycin at the dose of 500 mg orally 4
times per day (pediatric dose: 12.5 mg/kg 4 times per day with a maximum of 500 mg per dose) for 14-21 days) [11].
Such drugs are not recommended as first-line therapy for early LD since they are less effective, with cure rates of about
80% (12). A multicenter, double-blind, randomized, prospective trial comparing amoxicillin (500 mg 3 times per day
for 20 days) with azithromycin (500 mg once per day for 7 days) for the treatment of patients with erythema migrans
found  that  the  former  was  significantly  more  effective  than  azithromycin  for  complete  resolution  of  the  acute
manifestations of erythema migrans and for prevention of relapse in a 6-month period; of 217 evaluable subjects, only
4% of those treated with amoxicillin experienced relapse, compared with 16% of those treated with azithromycin [22].
Therefore,  patients  treated  with  macrolides  should  be  closely  observed  to  ensure  resolution  of  the  clinical
manifestations. In contrast to the second-generation cephalosporin cefuroxime and the third-generation cephalosporins
ceftriaxone, first-generation cephalosporins, such as cephalexin, are inactive in vitro against Borrelia burgdorferi and
are ineffective clinically. Importantly, ceftriaxone, while effective, is not superior to oral agents and is more likely than
the  recommended orally  administered  antimicrobials  to  cause  serious  adverse  effects.  Therefore,  ceftriaxone is  not
recommended for treatment of patients with early localized LD [11].
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4. EARLY DISSEMINATED DISEASE
4.1. Early Neuroborreliosis (Meningitis and Other Neurological Manifestations Lasting Less Than 6 Months)
According to the most recent recommendations on this topic [23], such a group of patients should be treated with a
single  14-day (range  10-28 days)  course  of  antibiotic  therapy.  In  most  European studies,  the  duration  of  treatment
ranged  from 10  to  14  days,  while  only  in  few studies  it  was  extended  to  28  days.  Interestingly,  the  occurrence  of
persistent residual symptoms after standard antibiotic therapy in some cases has led to speculations about surviving
bacteria and an eventual need for longer treatment duration, but there are no high quality data supporting a similar
assumption.
Patients with peripheral nervous system involvement (meninges, nerve roots, cranial and/or peripheral nerves) may
be  treated  with  both  oral  doxycycline  (200  mg/day,  divided  into  two  doses  daily;  pediatric  dose:  4  mg/kg)  and
intravenous therapies, including ceftriaxone (2 g single daily dose; pediatric dose: 50-75 mg/kg with a maximum of 2
g), penicillin G (generally 20 million U daily, divided into six doses every four hours, with a possible range of 18-24
million U/day; pediatric dose: 200-400 thousands U/kg/day, not exceeding 24 million U a day) or cefotaxime (3 g two
times daily or 2 g three times daily; pediatric dose: 200 mg/kg/die, divided in 3 doses daily, with a maximum of 6
g/day) [24, 25 - 27]. According to some studies, the three intravenous regimens present a similar efficacy [26, 27] and
doxycycline  and  intravenous  ceftriaxone  for  14  days  are  equally  effective  [28  -  31].  At  the  moment,  there  is  no
significant  data  suggesting  the  use  of  intravenous  drugs  over  oral  doxycycline  (which  is  easier  to  administer  and
cheaper) [23].
Pediatric population should be treated with the same drug options and timing of the adults [23], although a Swedish
study involving 203 children with early neuroborreliosis  has reported good results  with shorter  therapies (10 days)
based on intravenous beta-lactam antibiotics or oral doxycycline (contraindicated in children less than 8 years) [32].
Regarding patients with central nervous system involvement (encephalitis, myelitis), the only recommended therapy
is represented by intravenous ceftriaxone (2 g daily; pediatric dose: 50-75 mg/kg with a maximum of 2 per day) for 14
days [23].  Interestingly,  a  Swedish Slovenian study comparing intravenous ceftriaxone and oral  doxycycline in the
treatment of encephalitis has reported a good and comparable improvement in both groups of patients [29].
4.2. Myopericarditis and Atrioventricular Heart Blocks
Generally, for symptomatic patients (e.g. presenting syncope, dyspnea, or chest pain) and/or subjects with second-
or third-degree atrioventricular block or first-degree heart block with PR interval prolonged to 300 milliseconds, the
hospitalization with continuous monitoring is advised [33]. The management options for treating myopericarditis and
atrioventricular heart blocks include both oral and parenteral antibiotic therapy for 14 days (range 10-28 days) [11]. In
particular, hospitalized patients are treated with intravenously antibiotics, such as ceftriaxone (at the single dose of 2 g
daily;  pediatric  dose:  50-75  mg/kg  per  day  with  a  maximum  of  2  g  daily)  [11],  cefotaxime  (6  g  divided  into  3
doses/daily;  pediatric  dose:  150-200  mg/kg/day  with  a  maximum of  6  g  per  day)  [12]  or  penicillin  G  (0.5  million
U/kg/day,  divided  in  four-six  doses  daily,  with  a  maximum of  20  million  U/day)  [24],  albeit  there  are  no  relevant
clinical trials to support these therapeutic approaches. In case of advanced heart block, a temporary pacemaker may be
required (at least since the advanced heart block has been resolved) [34, 35]. The oral antibiotic treatment represents the
first choice for outpatients, with the same regimen used for manifestations of erythema migrans without carditis (see
above) [12].  In the literature,  there is no high-quality evidence to suggest that parenteral antibiotic therapy is more
effective than oral  antibiotic therapy in the treatment of Lyme-associated cardiac manifestations and that  antibiotic
therapy in general acts on them. Anyhow, antibiotic therapy is currently recommended in order to block the progression
of the cardiac involvement in patients with LD [34].
4.3. Skin Manifestations (Borrelial Lymphocytoma and Multiple Erythema Migrans)
Borrelial lymphocytoma may be treated with the same regimens used for erythema migrans (see above), but there
are no relevant clinical trials showing which is the best therapeutic approach [11, 12]. According to one study involving
65  patients  with  borrelial  lymphocytoma  of  the  ear  lobe  or  of  the  breast,  the  effectiveness  of  oral  doxycycline,
azithromycin and amoxicillin (administered at the same dosage than for single erythema migrans) is comparable [36].
However, the number of patients in these study is too low and pretreatment characteristics are too heterogeneous for a
reliable comparison of  the efficacy of  different  antibiotics,  consequently the optimal  agent,  dosage and duration of
therapy for borrelial lymphocytoma cannot be determined [11]. Importantly, the choice of treatment duration should
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take into account that the disappearance of the lymphocytoma takes longer in patients with prolonged duration prior to
treatment [36, 37].
According to the European Concerted Action on Lyme Borreliosis, multiple erythema migrans are usually treated
with intravenous ceftriaxone for 3 weeks (at the single dose of 2 g daily; pediatric dose: 50-75 mg/kg per day with a
maximum of  2 g daily),  oral  amoxicillin  for  14-30 days (1500 mg/day divided in  3 doses daily;  pediatric  dose:  50
mg/kg/day) or doxycycline for 14-30 days (100-150 mg in 2 doses/day) [38]. A Finnish study involving 16 patients
with multiple erythema migrans, showed a cure rate of 100% (4/4 patients), 80% (4/5 patients, with one only partially
healed)  and  86%  (6/7)  for  amoxicillin,  doxycycline  and  ceftriaxone,  respectively  [39].  One  larger  randomized
controlled  trial  on  140 patients  with  early  disseminated  LD (  most  of  them presenting  multiple  erythema migrans)
treated either for 14 days with ceftriaxone or for 21 days with doxycycline showed no significant differences in cure
rates between the two groups [26].
5. LATE DISEASE
5.1. Arthritis
Patients suffering from arthritis without evidence of neurological involvement can usually be treated successfully
with oral antibiotics for 28 days. In particular, doxycycline, amoxicillin or cefuroxime axetil are currently used at the
same adult or pediatric dosage of early localized disease (see above) [11]. The concomitant use of probenecid with
amoxicillin is not advised since probenecid may impair the penetration of beta-lactam antibiotics into brain parenchyma
[40, 41]. A cost-effective analysis has shown that for most patients with Lyme arthritis, intravenous therapy appears to
be  no  more  effective  than  oral  therapy,  is  more  likely  to  result  in  serious  complications,  and  is  substantially  more
expensive,  thus  supporting  that  oral  antibiotics  should  be  considered  as  the  first  therapy  for  Lyme  arthritis  in  the
absence of  concomitant  neurologic involvement [42].  However,  it  is  important  to underline that  a  small  number of
patients treated with oral agents may subsequently manifest overt neuroborreliosis, requiring intravenous therapy with a
beta-lactam antibiotic for resolution [11].
Patients  with  arthritis  plus  objective  evidence  of  neurological  disease  should  receive  parenteral  therapy  with
ceftriaxone (at the single dose of 2 g daily; pediatric dose: 50-75 mg/kg per day with a maximum of 2 g daily) or, in
alternative, cefotaxime or penicillin G at their standard dosage (see above) for 2-4 weeks [11, 43, 44]. According to
some studies, in most cases 2 weeks of intravenous therapy with ceftriaxone is enough for resolving the illness [45, 46].
Compared  with  penicillin,  the  advantages  of  ceftriaxone  are  its  excellent  cerebro-spinal  fluid  penetration  and  long
serum half-life, which permits once-per-day dosing. However, ceftriaxone may cause biliary complications, which are
not reported with cefotaxime administration [44].
Generally,  in  cases  of  arthritis  not  completely  resolved  after  a  recommended  course  of  oral  antibiotic  therapy,
another 4 week-course of oral antibiotics is advised. While, in case of complete lack of response (or worsening) after
adequate therapy, patients are more suitable to undergo 2-4 week-course of intravenous ceftriaxone [11]. For inpatients,
some Authors suggested the use of intravenous cefotaxime (three divided doses) because of the lesser incidence of
biliary side-effects. Anyhow, clinicians should wait several months before initiating re-treatment with antibiotics due to
the possible slow resolution of inflammation after treatment. During this period, non steroidal anti-inflammatory drugs
may  be  used  [47],  while  intra-articular  injections  of  corticosteroids  are  not  recommended  [11].  For  patients  with
negative PCR results of synovial fluid, in whom joint swelling is persistent or recurrent even after the retreatment, only
symptomatic therapies are recommended, including non steroidal anti-inflammatory drugs, intra-articular injections of
corticosteroids,  hydroxychloroquine,  and/or  also  arthroscopic  synovectomy  to  reduce  the  swelling  (if  persistent
synovitis is associated with significant pain or limitation of function) [48]. A study on 20 patients who underwent the
latter procedure for refractory chronic Lyme arthritis of the knee showed that 16 cases (80%) had resolution of joint
inflammation within the first  month or soon thereafter  [49].  Immunological  features,  genetic factors and pathogen-
related factors might all contribute to the evolution into a rheumatoid-like disease. Even though a significant portion of
treatment-refractory  patients  with  Lyme  arthritis  has  been  noted  in  several  studies,  the  general  consensus  is  that
antibiotic treatment remains the cornerstone of therapy [24].
5.2. Late Neuroborreliosis (Peripheral and Central Neurological Manifestations Lasting More Than 6 Months)
Adult patients with symptoms confined to the peripheral nervous system should be treated with oral doxycycline
(200 mg daily,  divided into two doses per day) or intravenous ceftriaxone (2 g once a day) for 3 weeks (range 2-4
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weeks) [23]. According to some authors, intravenous penicillin (20 million U daily for 10 days) is a possible parenteral
alternative  to  ceftriaxone  [23,  27,  50].  Albeit  there  is  no  high  quality  evidence,  the  outcomes  of  the  oral  and  the
intravenous therapeutic strategy seem to be comparable. Indeed, a Swedish study on over 40 patients suffering from
acrodermatitis chronica atrophicans and late neuroborreliosis with peripheral involvement showed a similar response
rate on neurological manifestations between a group (21 patients) receiving oral doxycycline for 3 weeks and a group
(21  patients)  receiving  intravenous  penicillin  for  2  weeks  followed  by  oral  doxycycline  for  other  2  weeks  [50].
Similarly,  another  analysis  of  10  patients  with  late  neuroborreliosis  with  peripheral  involvement  showed  equal
improvement after 14 days of oral doxycycline as after 14 days of intravenous ceftriaxone [31]. Adult patients with
neuroborreliosis  involving  the  central  nervous  system  (myelitis,  encephalitis,  vasculitis)  should  be  treated  with
intravenous ceftriaxone (2 g daily, once a day) for 3 weeks [23]. An European open-label study of late neuroborreliosis
(defined as non-specific central nervous system symptoms, without cerebrospinal fluid pleocytosis or other neurological
findings) showed similar improvement rates (59% vs 67% respectively) six months after treatment with four weeks of
oral doxycycline versus two weeks of intravenous ceftriaxone followed by two weeks of oral doxycycline [51].
There are not enough data to support the use of steroids alone or in combination with antibiotics in neuroborreliosis
[23].
5.3. Ocular Manifestations (Keratitis, Uveitis)
There are no high quality recommendations on such manifestations of LD because of the lack of evaluable data on
ophthalmologic complications, which are very rare [11]. Anyway, the best approach for these patients might be a trial of
intravenous antibiotic therapy (ceftriaxone at the dose of 50 mg/kg/day for 2-3 weeks). If patients respond to treatment,
ocular LD is diagnosed, and no other therapy is needed [52, 53]. Other authors suggest the use of doxycycline for 28
days  (4  mg/kg/day  in  two  divided  doses,  with  a  maximum of  200  mg/day;  after  8  years  of  age)  [24].  In  cases  of
recurrences  of  ocular  manifestations,  once  adequate  intravenous  therapy  has  been  given,  some  authors  advise  a
judicious course of topical or systemic corticosteroids [52, 54]. Anyhow, they should not be used in patients in whom
an adequate antibiotic therapy has not been performed [52 - 54].
5.4. Acrodermatitis Chronica Atrophicans
According to the European Concerted Action on Lyme Borreliosis,  acrodermatitis  chronica atrophicans may be
treated with oral drugs, including amoxicillin (3 x 500-1000 mg/day; pediatric dose: 25-50 mg/kg/day) and doxycycline
(2 x 100 mg/day; contraindicated in children less than 8 years), or intravenous ceftriaxone (2 g/day; pediatric dose:
50-100 mg/kg/day). The treatment duration for all three drugs is 21 days (range 14-30 days) (38). An alternative therapy
advised by some authors is intravenous cefotaxime 50 mg/kg/day in one dose (maximum dose 2,000 mg/day) for at
least  4  weeks  [55].  Importantly,  high  quality  controlled  studies  comparing  oral  and  parenteral  antibiotic  for  the
treatment of acrodermatitis chronica atrophicans are missing [11].
6.  JARISCH-HERXHEIMER  REACTION  AND  THERAPEUTIC  APPROACH  REGARDING  SPECIAL
CATEGORIES/OTHER POSSIBLE BORRELIA-RELATED MANIFESTATIONS
6.1. Jarisch-Herxheimer Reaction
The  Jarisch-Herxheimer  reaction  is  a  treatment-related  transient  immunological  phenomenon.  It  is  due  to  the
increase in circulating toxins and/or inflammatory cytokines associated with the lysis of the spirochetes, induced by the
antimicrobial treatment. Clinically, it consists in short-term constitutional symptoms, including fever, chills, headache,
myalgia, arthralgia, besides exacerbation of existing cutaneous lesions. This reaction occurs within 24 hours after the
start of any recommended antimicrobial agent and it resolves without serious consequences within 24 hours, with no
evidence of recurrence and any relationship with the outcome of the current treatment [11]. There is no conformity
about incidence data of this phenomenon in relation to different spirochetes and to different therapeutic or prophylactic
strategies of LD, however, an increase in the incidence may be expected among patients co-infected with HIV and other
infectious diseases including syphilis [56].
6.2. Pregnant Women
Pregnant  (and  lactating)  patients  may  be  treated  identically  to  non  pregnant  patients  with  the  same  disease
manifestation, except that doxycycline should be avoided [11]. Interestingly, some American practitioners prescribe a
10-14-day course of prophylactic amoxicillin for pregnant women after Ixodes scapularis tick bites, since case reports
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have suggested that LD during pregnancy may be associated with adverse outcomes for the fetus [57 - 59]. However, a
large amount of data from clinical and epidemiological studies suggest that there are no fetal risks when a pregnant
woman with LD is treated with adequate antibiotic therapy [60 - 62]. An example is a Slovenian prospective study of 58
consecutively enrolled pregnant women with typical erythema migrans: 13 patients (22.4%) acquired borrelial infection
in the first trimester of pregnancy, 26 (46.6%) in the second trimester, and 18 (31%) in the third trimester. All patients
were  treated  for  14  days:  2  (3.4%)  with  phenoxymethylpenicillin  (1  million  IU  thrice  per  day),  3  (5.2%)  with
benzylpenicillin (10 million units twice per day), and 53 (91.4%) with ceftriaxone (2 g daily). In most cases (51/58
women; 87.9%), the pregnancy was normal and the infants (all born at term) were clinically healthy. Of the remaining 7
pregnancies, 1 child born at term was found to have urologic abnormalities at 7 months of age, 1 ended with a missed
abortion and 5 with preterm birth (1 of the preterm babies had heart abnormalities). However, a causal relationship
between borrelial infection and fetal adverse effects has not been proven [60].
6.3. Post-Treatment Lyme Disease Syndrome
About 10 to 20% of patients treated for LD with an appropriate 2-4 week course of antibiotics may experience
lingering  symptoms  similar  to  fibromyalgia  (e.g.,  fatigue,  pain,  joint  and  muscle  aches)  or,  more  rarely,  they  may
present other manifestations such as cognitive complaints, radicular pain, paresthesias or dysesthesias [11]. Albeit often
known as "chronic LD", this condition is defined as post-treatment LD syndrome (PTLDS) [63] ; it may last for weeks,
months,  or  longer  [11,  12].  Importantly,  some authors  recognize  two clinical  pictures,  namely  “post-Lyme disease
symptoms” if manifestations persist for less than 6 months and “post-Lyme disease syndrome” if they are disabling and
persist for 6 months or longer [64]. The exact cause of PTLDS is not yet known, but most medical experts believe that it
is the result of residual damage to tissues and the immune system that occurred during the infection. In contrast, other
authors think that these symptoms reflect persistent infection with Borrelia burgdorferi [23, 65, 66]. Hypothetically, the
persistence of Borrelia is attributed to its residency within the cell and to the development of biologically less active
permanent forms (sphaeroplasts, encystment). Furthermore, Borrelia was also shown to develop biofilms with the effect
of  resisting  complement  and  typical  shedding  (casting  off  antibodies  from  the  surface  of  the  bacterium).  Other
mechanisms,  including  changing  protein  antigens  located  on  the  membrane,  the  loss  of  plasmids  and  processes  to
inactivate  complement,  might  also  led  the  pathogen  to  evade  the  immune  system  [66].  Anyhow,  further  study  are
needed to clarify such open questions [63]. PTLDS has not been shown in any controlled trials to be responsive to
antibiotic  therapy  [67].  For  example,  a  relatively  recent  study  failed  to  show  a  benefit  of  treatment  with  2  g  of
intravenous ceftriaxone daily for 30 days,  followed by oral doxycycline at  200 mg/d for 60 days [68].  Thus, at  the
moment, antibiotic therapy is not recommended for patients with PTLDS after adequate treatment regimens for LD,
while symptomatic treatments may be administered to control the symptoms [11]. However, according to some authors,
the use of hydroxychloroquine or metronidazole, in combination with standard antibiotics, may help in resistant chronic
cases since such drugs have an effect on encysted forms [68]. Anyhow, no high quality evidence supports a similar
approach.
6.4. Controversial Skin Manifestations
The role of Bb in sclerotic or degenerative conditions of the skin other than acrodermatitis chronica atrophicans
remains unclear. For morphea, lichen sclerosus and athrophicus and anetodermia [69 - 73] a possible Bb etiology was
repeatedly suggested on the basis of clinical, serological, immunohistochemical, molecular biology and culture, but for
other  frameworks  such  as  granuloma  annulare,  pityriasis  rosea,  pityriasis  lichenoides,  erythema  nodosum,  papular
acrodermatitis of Giannotti Crosti, Raynaud's syndrome, sarcoidosis, Reiter's syndrome, idiopathic nodular panniculitis
(Pfeifer-Weber-Christian disease) and some lymphomas [74 - 80] reports are occasional and therefore require further
confirmation. However both in anecdotal cases and in case series one of the validation criteria of the association was the
improvement after antibiotic therapy [80]. Oral drugs, including amoxicillin (3 x 500-1000 mg/day) and doxycycline (2
x  100  mg/day),  or  intravenous  ceftriaxone  (2  g/day),  usually  for  2-3  weeks  (albeit  longer  treatment  have  been
reported), have been used alone or in association with the typical drugs for the different diseases [69 - 82]. Naturally,
since there are no certainties about the above mentioned associations there are no well-defined therapies [82].
6.5. Coinfections
Therapeutic resistance can be related to coinfections, that should be considered in patients who present with more
severe initial symptoms in comparison to those commonly observed in LD alone and especially in patients who have
high-grade fever despite receiving an appropriate antibiotic therapy for LD [11, 55]. When patients have leucopenia and
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neutropenia after the treatment, the suspect is a coinfection by Anaplasma phagocytiphilum infection, that is transmitted
by the tick Ixodes ricinus, the same vector of Borrelia. A. phagocytophilum, the causative agent of human granulocytic
anaplasmosis, is a rickettsial organism that produces an acute febrile systemic illness, constitutional symptoms, and
laboratory  abnormalities  such  as  leukopenia,  thrombocytopenia,  and  elevated  levels  of  hepatic  transaminases  [83].
Doxycycline is recommended as the treatment of choice for patients who are suspected of having symptomatic human
granulocytic  anaplasmosis.  The  dosage  regimen  for  adults  is  100  mg  orally  twice  daily  for  10  days  [55,  84].
Babesiosis is a malaria-like protozoan infection of erythrocytes that is transmitted by Ixodes spp. ticks [83, 85, 86]. It
may also be acquired from blood transfusions. Several species of Babesia are capable of causing human disease; the
most important of these are B. microti in the US and B. divergens in Europe. Clinical babesiosis is similar to malaria,
with an onset of high fever (40° C), malaise, myalgia, fatigue and anemia. Also a hepatosplenomegaly can be present
[87]. Hemolytic anemia can last from a few days to a few months in severe cases, which tend to occur more frequently
in the elderly and in splenectomized.  The infestation with Babesia microti  results  milder,  self-limited and possibly
treatable so unspecific. The combination of either atovaquone (750 mg orally twice a day) plus azithromycin (500-1000
mg on day 1 and 250 mg orally once per day thereafter) or clindamycin (300-600 mg every 6 hours intravenously or
600 mg every 8 hours orally) plus quinine (650 mg every 6-8 h orally) for 7-10 days is the initial therapy that should be
considered for patients with babesiosis. Clindamycin and quinine should be given for those with severe babesiosis [55].
Rickettsia species (the majority is represented by R. Helvetica and  monacensis) is another agent of possible co-
infection [88, 89]. The clinical onset of rickettsiosis is characterized by fever and a small papule of 1-1.5 cm in diameter
that developed in a small ulcer with a dark crust that leaves a scar when it heals. There is a regional lymphadenopathy.
Then an intermittent fever, for a week, with chills, profuse sweating, headache, photophobia, and muscle aches. During
the course of fever, generalized maculopapular rash appears early with intraepidermal vesicles, which spares the palms
of hands and soles of the feet. The antibiotics of choice are tetracycline, doxycycline or chloramphenicol, at the doses
used for other rickettsial exanthematous manifestations. Also ciprofloxacin and macrolides are active [90].
6.6. Baggio-Yoshinary Syndrome
Baggio-Yoshinary syndrome is a Brazilian zoonosis, a new tick borne disease caused by Borrelia spp, possibly a
Borrelia  burgdorferi  sensu  lato  genetically  modified  or  a  new  Borrelia  species,  transmitted  by  ticks  of  genus
Amblyomma and Rhipicephalus [91, 92]. The first case was described in 1992 in Brazil, initially as a case resembling
LD, then called Baggio-Yoshinary syndrome because of some epidemiological, clinical, and laboratory differences
from LD [93, 94]. Clinically it mimics symptoms of LD but differs from it mainly for high frequencies of recurrent
episodes and from the autoimmune component. In fact, patients suffering from Baggio-Yoshinary syndrome  often
present  antinuclear  antibodies,  anti-cardiolipin  antibodies,  anti-neutrophil  cytoplasmic  antibodies  and  antineuronal
antibodies  [95].  The  treatment  of  such  a  disease  depends  on  the  stage.  Generally,  in  presence  of  neurological
complications a therapy with ceftriaxone 2 g daily for 30 days followed by two or three months of doxycycline 100 mg
twice a day is recommended [93].
CONCLUSION
LD is  a  complex,  multisystem  and  polymorphic  illness  that  is  easy  to  treat  in  most  cases.  Albeit  its  reference
treatment  is  represented  by  antibiotics,  currently  there  is  no  univocal  consensus  about  the  drug  selection,  route  of
administration,  dose  and  duration  of  therapy  for  the  various  manifestations/stages  of  the  disease.  In  general,  the
therapeutic  outcome  for  LD seems  quite  favourable  and  similar  among  the  different  advised  antibiotics,  but  about
10-20% of  patients  may  show persistent  or  recurrent  symptoms  despite  appropriate  treatment.  Large  double-blind,
controlled, long-term prospective trials are needed to assess the precise effectiveness and role of the various therapies
and develop strategies for those patients not responding to the current treatment options.
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